VANCOUVER, British Columbia, June 10, 2026 – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial.
The shipment comprises psilocybin biomass and finished 5mg psilocybin capsules, supplied to support a planned Phase 2 clinical trial in the United Kingdom. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression (TRD). Optimi intends to announce the trial partner and indication at a later date.
The exported product was manufactured at Optimi’s GMP facility in Princeton, British Columbia, Canada, and shipped under export authorization issued by Health Canada and import authorization from the UK Home Office. The export follows Optimi’s recently announced completion of a GMP production run of its 5mg psilocybin drug product, a portion of which was earmarked to support clinical research in Europe.
Optimi cultivated the biomass and produced the finished capsules in-house, extracting the active pharmaceutical ingredient (API) using its proprietary methods, all under its Health Canada Drug Establishment Licence (DEL). The ability to supply both biomass and finished drug product from a single licensed facility positions Optimi as a vertically integrated GMP supplier for regulated psychedelic research and medicine.
“This is our first shipment into the United Kingdom, and it is the same psilocybin we already supply to patients in Australia,” said Dane Stevens, CEO and Co-Founder of Optimi. “We can serve a commercial market and a clinical trial from the same GMP facility, on our own licence. That is a rare position, and one we have spent years building.”
Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, in support of both patient access and clinical research. Inquiries regarding product for special access programs and clinical trial supply may be directed to sales@optimihealth.ca.
About Optimi Health Corp.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.
Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
